August 22, 2024
Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success
Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
Walgreens’ Three-Year Revival Plan: Strategic Store Closures and Enhanced Healthcare Services
Walgreens, retail pharmacy, store closures, healthcare services, profitability, strategic review
WuXi Biologics’ ADC Spinout Sees Revenue Surge Amid Biosecure Threat
WuXi Biologics, ADC spinout, revenue jump, Biosecure risk, CRDMO, bioconjugate market
Astellas Employee Indicted by China’s Prosecutors on Espionage Charges
Astellas Pharma, China, Japan, espionage, indictment, diplomatic tensions
Biopharma Layoff Tracker 2024: Industry Continues to Downsize Amid Financial Pressures
Biopharma layoffs, job cuts, restructuring, financial pressures, industry trends
BridgeBio Unveils GondolaBio with $300M Investment, Transfers Key Programs to Joint Venture
BridgeBio, GondolaBio, Joint Venture, $300M Investment, Genetic Therapies, Biopharma Startup
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
FDA Rejects Regeneron’s Blood Cancer Bispecific, Delaying Competition with J&J and Pfizer
Regeneron, FDA rejection, blood cancer bispecific, linvoseltamab, multiple myeloma, J&J, Pfizer
Aadi Bioscience Cuts 80% of R&D Staff Amid Fyarro Expansion Setbacks
Aadi Bioscience, R&D workforce, Fyarro, expansion efforts, layoffs, pharmaceutical industry